Buy Tesamorelin 10mg

Tesamorelin is a synthetic analogue of human GHRH in which the native 44-amino-acid sequence is conjugated at its N-terminus to a trans-3-hexenoic acid group via a stable amide bond. This modification substantially increases resistance to dipeptidyl peptidase IV (DPP-IV) proteolysis — the primary enzyme responsible for rapid inactivation of native GHRH in plasma — extending the half-life from approximately seven minutes for native GHRH to roughly twenty-six minutes for tesamorelin. While modest compared to the DAC-modified CJC-1295, this extension is sufficient for clinically meaningful pituitary stimulation when tesamorelin is administered as a daily subcutaneous injection. Tesamorelin binds the pituitary GHRH receptor (GHRHR) as a full agonist, activating the identical Gαs-cAMP-PKA cascade that mediates endogenous GHRH signalling. Receptor occupancy elevates intracellular cAMP within anterior pituitary somatotroph cells, activating protein kinase A, phosphorylating CREB, and stimulating both transcription of the GH1 gene and calcium-dependent exocytosis of pre-formed GH secretory granules. Critically, tesamorelin preserves the hypothalamic-pituitary-somatotroph feedback axis: as GH rises and drives IGF-1 synthesis, hypothalamic somatostatin release increases to attenuate subsequent GH pulses, preventing the runaway GH elevation seen with exogenous GH administration. The mechanism by which tesamorelin reduces visceral adipose tissue (VAT) specifically — rather than subcutaneous fat — relates to the distinctive GH receptor density and downstream signalling characteristics of visceral adipocytes. VAT depots express higher concentrations of GH receptors than subcutaneous fat and are more sensitive to GH-mediated lipolytic signalling. GH activates hormone-sensitive lipase in adipocytes via JAK2-mediated phosphorylation of perilipin and HSL, mobilising stored triglycerides into free fatty acids. In visceral adipocytes, GH simultaneously suppresses the expression of lipoprotein lipase (LPL) — the enzyme responsible for re-esterification of circulating fatty acids into adipocyte triglycerides — creating a net efflux of stored fat from visceral depots. The metabolic consequences of tesamorelin-mediated GH normalisation extend beyond VAT reduction. IGF-1 elevation through the JAK2/STAT5/IGF-1 axis improves insulin sensitivity in peripheral tissues, enhances lipid oxidation, and promotes nitrogen retention in skeletal muscle. In HIV-infected patients on antiretroviral therapy — the FDA-approved indication — these metabolic improvements translate to significant reductions in cardiovascular disease risk markers including the trunk-to-limb fat ratio, triglycerides, and non-HDL cholesterol. In non-HIV healthy adults with central adiposity, the mechanism is equally operative, producing comparable VAT reductions in investigational settings.

Tesamorelin is the strongest choice for individuals whose primary goal is visceral fat reduction, particularly those with documented central adiposity, elevated waist circumference, metabolic syndrome characteristics, or elevated cardiovascular risk. Its FDA approval provides an unparalleled evidence base within the peptide category, and its Phase III data support realistic expectations of 15–20% visceral fat reduction over 26 weeks of daily administration. It is not primarily an anabolic peptide — lean mass changes are modest compared to combination secretagogue protocols — but its metabolic and cardiovascular risk-reduction profile is unmatched in the class. The 10 mg vial size is suited to a multi-week research supply at the standard 2 mg/day dosing used in pivotal clinical trials. When evaluating sources, insist on HPLC purity certificates confirming the trans-3-hexenoic acid conjugation as well as the full GHRH 1-44 sequence — unlike shorter GHRH fragments, tesamorelin contains the complete 44-amino-acid GHRH sequence, and any truncation will materially reduce receptor binding affinity. Mass spectrometry peptide identity confirmation is essential. Reconstitute with sterile or bacteriostatic water to a concentration of 1–2 mg/mL and refrigerate; do not freeze reconstituted product. Dosing in the clinical setting is 2 mg subcutaneously per day, injected into the abdominal region below the navel. Rotation of injection sites within the abdominal quadrant prevents localised lipodystrophy. Users should fast for 90–120 minutes before dosing and avoid high-fat meals within two hours of injection to maximise GH response. Evening dosing is preferred to amplify the nocturnal GH surge. IGF-1 testing at baseline, eight weeks, and 26 weeks allows dose assessment; fasting glucose and HbA1c monitoring at each timepoint is clinically warranted given tesamorelin's effect on insulin sensitivity.

Tesamorelin stands apart from all other research peptides in this guide by virtue of its FDA approval and Phase III clinical evidence base. No other secretagogue or performance peptide has been evaluated in regulatory-quality randomised controlled trials for a body composition endpoint. This distinction is clinically significant: the ENCORE and RADIANCE data provide an unusually rigorous basis for expected outcomes (15–20% VAT reduction over 26 weeks), making tesamorelin the most evidence-supported option for individuals specifically targeting visceral adiposity. Compared to CJC-1295 with DAC — a longer-acting GHRH analogue — tesamorelin has the advantage of full FDA approval history and Phase III data, but requires daily injection versus weekly or biweekly dosing for CJC-1295 with DAC. CJC-1295 paired with ipamorelin offers broader anabolic benefits including lean muscle accrual and sleep quality improvements that tesamorelin does not specifically address. For users whose goals include both visceral fat reduction and lean tissue support, a sequential approach — tesamorelin for 26 weeks to address VAT, followed by or combined with a CJC-1295/ipamorelin protocol — is a strategy employed in advanced clinical practice. Relative to sermorelin, tesamorelin offers superior visceral fat efficacy due to its complete 44-amino-acid GHRH sequence providing full receptor engagement, its DPP-IV resistance, and its significantly larger body of clinical data. Sermorelin at standard doses produces smaller GH pulses and commensurately lesser VAT impact, making it more appropriate for general somatopause management than targeted metabolic recomposition. For any user whose primary measurable goal is reduction of visceral fat confirmed by imaging, tesamorelin is the scientifically defensible first choice within the peptide category.